Profound Medical (TSE:PRN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Profound Medical has appointed Tom Tamberrino as Chief Commercial Officer to drive the widespread adoption of its TULSA technology, a promising treatment for prostate disease. This strategic move comes ahead of anticipated changes in reimbursement codes that could significantly boost the company’s market position.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.